Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer
IntroductionThis study aimed to assess the diagnostic efficacy of the PRIMARY score, based on the 18F-labeled prostate-specific membrane antigen (PSMA-1007) positron emission tomography (PET)/computed tomography (CT) with multiparametric magnetic resonance imaging (mpMRI) PI-RADS, in detecting clini...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1589212/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688803327868928 |
|---|---|
| author | Zhilong Ma HaiTong Hao HaiTong Hao Jian Chen Jian Chen Tong Pan Tong Pan Qian Zhao YanMei Li |
| author_facet | Zhilong Ma HaiTong Hao HaiTong Hao Jian Chen Jian Chen Tong Pan Tong Pan Qian Zhao YanMei Li |
| author_sort | Zhilong Ma |
| collection | DOAJ |
| description | IntroductionThis study aimed to assess the diagnostic efficacy of the PRIMARY score, based on the 18F-labeled prostate-specific membrane antigen (PSMA-1007) positron emission tomography (PET)/computed tomography (CT) with multiparametric magnetic resonance imaging (mpMRI) PI-RADS, in detecting clinically significant prostate cancer (csPCa).Materials and MethodsIn this retrospective cohort study, 137 patients with suspected prostate cancer (PCa) underwent [18F]PSMA-1007 PET/CT and mpMRI before transrectal ultrasound (TRUS)-guided needle biopsy was performed. Patients were categorized into csPCa and non-csPCa groups based on histopathological findings. The diagnostic performance of total prostate-specific antigen (TPSA), maximum standardized uptake value (SUVmax), the standardized Prostate Imaging Reporting and Data System (PI-RADS v2. 1) of mpMRI, and the PRIMARY score was evaluated using receiver operating characteristic (ROC) curves. The area under the curve (AUC), sensitivity, and specificity were calculated. Factors with a P-value <0.05 from the univariate analysis were included in a binary logistic regression model to develop a predictive model. Differences in the AUCs for TPSA, SUVmax, PI-RADS v2.1, the PRIMARY score, and the combined model were compared using MedCalc software. Statistical significance was set at P<0.05.ResultsAmong the 137 patients evaluated, 67.2% (92) were in csPCa and 32.8% (45) in the non-csPCa group (15 with low-grade PCa [GS 3 + 3] and 30 with benign prostatic hyperplasia or acute or chronic prostatitis). TPSA, SUVmax, PI-RADSv2.1, and the PRIMARY score significantly differed between the two groups (P<0.013). The AUCs for TPSA, SUVmax, PI-RADSv2.1, and PRIMARY score were 0.699, 0.898, 0.878, and 0.910, respectively, with corresponding diagnostic sensitivities of 53.3%, 87.0%, 90.2%, and 83.7%, and specificities of23.0%, 65. 1%, 42.6%, and 58.5%, respectively. The predictive ROC curve analysis of the model revealed an AUC of 0.968, with 91.3% sensitivity, and 84.6% specificity. MedCalc analysis showed that the AUC of the model was superior compared with that of SUVmax, PI-RADS v2.1 Score, and the PRIMARY score. The difference was statistically significant (Z= 2.273, 3.485, 2.761; P=0.023, 0.000, 0.005).ConclusionsThe 5-grade PRIMARY score, derived from [18F]PSMA-1007 PET/CT in conjunction with the PI-RADSv2.1 score, offers enhanced discrimination of csPCa. |
| format | Article |
| id | doaj-art-63e2f4c05a2b435f8ff6304a0aa97706 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-63e2f4c05a2b435f8ff6304a0aa977062025-08-20T03:21:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15892121589212Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancerZhilong Ma0HaiTong Hao1HaiTong Hao2Jian Chen3Jian Chen4Tong Pan5Tong Pan6Qian Zhao7YanMei Li8Nuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaNuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaCollege of Clinical Medicine, Ningxia Medical University, Yinchuan, ChinaNuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaCollege of Clinical Medicine, Ningxia Medical University, Yinchuan, ChinaNuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaCollege of Clinical Medicine, Ningxia Medical University, Yinchuan, ChinaNuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaNuclear Medicine Department, General Hospital of Ningxia Medical University, Yinchuan, ChinaIntroductionThis study aimed to assess the diagnostic efficacy of the PRIMARY score, based on the 18F-labeled prostate-specific membrane antigen (PSMA-1007) positron emission tomography (PET)/computed tomography (CT) with multiparametric magnetic resonance imaging (mpMRI) PI-RADS, in detecting clinically significant prostate cancer (csPCa).Materials and MethodsIn this retrospective cohort study, 137 patients with suspected prostate cancer (PCa) underwent [18F]PSMA-1007 PET/CT and mpMRI before transrectal ultrasound (TRUS)-guided needle biopsy was performed. Patients were categorized into csPCa and non-csPCa groups based on histopathological findings. The diagnostic performance of total prostate-specific antigen (TPSA), maximum standardized uptake value (SUVmax), the standardized Prostate Imaging Reporting and Data System (PI-RADS v2. 1) of mpMRI, and the PRIMARY score was evaluated using receiver operating characteristic (ROC) curves. The area under the curve (AUC), sensitivity, and specificity were calculated. Factors with a P-value <0.05 from the univariate analysis were included in a binary logistic regression model to develop a predictive model. Differences in the AUCs for TPSA, SUVmax, PI-RADS v2.1, the PRIMARY score, and the combined model were compared using MedCalc software. Statistical significance was set at P<0.05.ResultsAmong the 137 patients evaluated, 67.2% (92) were in csPCa and 32.8% (45) in the non-csPCa group (15 with low-grade PCa [GS 3 + 3] and 30 with benign prostatic hyperplasia or acute or chronic prostatitis). TPSA, SUVmax, PI-RADSv2.1, and the PRIMARY score significantly differed between the two groups (P<0.013). The AUCs for TPSA, SUVmax, PI-RADSv2.1, and PRIMARY score were 0.699, 0.898, 0.878, and 0.910, respectively, with corresponding diagnostic sensitivities of 53.3%, 87.0%, 90.2%, and 83.7%, and specificities of23.0%, 65. 1%, 42.6%, and 58.5%, respectively. The predictive ROC curve analysis of the model revealed an AUC of 0.968, with 91.3% sensitivity, and 84.6% specificity. MedCalc analysis showed that the AUC of the model was superior compared with that of SUVmax, PI-RADS v2.1 Score, and the PRIMARY score. The difference was statistically significant (Z= 2.273, 3.485, 2.761; P=0.023, 0.000, 0.005).ConclusionsThe 5-grade PRIMARY score, derived from [18F]PSMA-1007 PET/CT in conjunction with the PI-RADSv2.1 score, offers enhanced discrimination of csPCa.https://www.frontiersin.org/articles/10.3389/fonc.2025.1589212/full[18 F]F-PSMA-1007positron emission tomography/computed tomographymultiparametric magnetic resonance imagingprostate cancermolecular probe |
| spellingShingle | Zhilong Ma HaiTong Hao HaiTong Hao Jian Chen Jian Chen Tong Pan Tong Pan Qian Zhao YanMei Li Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer Frontiers in Oncology [18 F]F-PSMA-1007 positron emission tomography/computed tomography multiparametric magnetic resonance imaging prostate cancer molecular probe |
| title | Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer |
| title_full | Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer |
| title_fullStr | Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer |
| title_full_unstemmed | Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer |
| title_short | Diagnostic value of [18F]PSMA-1007 PET/CT based on PRIMARY score combined with mpMRI in clinically significant prostate cancer |
| title_sort | diagnostic value of 18f psma 1007 pet ct based on primary score combined with mpmri in clinically significant prostate cancer |
| topic | [18 F]F-PSMA-1007 positron emission tomography/computed tomography multiparametric magnetic resonance imaging prostate cancer molecular probe |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1589212/full |
| work_keys_str_mv | AT zhilongma diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT haitonghao diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT haitonghao diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT jianchen diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT jianchen diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT tongpan diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT tongpan diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT qianzhao diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer AT yanmeili diagnosticvalueof18fpsma1007petctbasedonprimaryscorecombinedwithmpmriinclinicallysignificantprostatecancer |